biostudies-literatureUnknown69(3)Carrasco-Sanchez FJ<h4>Background</h4>This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.<h4>Materials and methods</h4>A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.<h4>Results</h4>Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and Endocrinologia, diabetes y nutricion209-218https://www.ebi.ac.uk/biostudies/studies/S-EPMC8570981biostudies-literature[Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19].PMC8570981Carrasco-Sanchez FJRuiz Quintero MAMerino-Torres JFGargallo MAPines Corrales PJGomez-Huelgas ROrozco-Beltran DCarretero-Anibarro Efalse[Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19].<h4>Background</h4>This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.<h4>Materials and methods</h4>A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.<h4>Results</h4>Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and 2022-01-01T00:00:00Z2022 Mar2025-06-01T00:30:15.726Z2025-06-01T00:30:15.726ZS-EPMC85709813477872110.1016/j.endinu.2021.10.003